Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VK2735 in Obese Adults Without Comorbidities
NCT07838740Phase 1Recruiting
- Sponsor
- Viking Therapeutics
- Start
- Nov 2025
- Primary completion
- May 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of VK-2735 in obesity (18 arms), sponsored by Viking Therapeutics. Primary endpoint: Safety and Tolerability at 33 weeks. Started Nov 2025; status: recruiting.
02
Drugs
VK-2735
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07838740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07838740.